Farydak

No, Farydak (panobinostat) has been discontinued and is no longer available in the United States. If this medication is necessary as part of your chemotherapy regimen, your provider can apply for access to Farydak (panobinostat) through Project Facilitate, which is a FDA program that allows certain people with life-threatening conditions to try medications that aren't on the market.

Farydak (panobinostat) was approved by the FDA through its Accelerated Approval Program in 2015. But the manufacturer (Secura Bio) voluntarily discontinued this medication in 2021. It was taken off the market because the manufacturer couldn't complete all the clinical studies it needed to do under the Accelerated Approval Program. Therefore, the manufacturer wasn't able to confirm beneficial health outcomes after this medication was approved (in this case, whether Farydak (panobinostat) slows down cancer growth and helps people with multiple myeloma live longer).

There are many different factors that a provider must consider in choosing the right multiple myeloma treatment for you, such as your medical history, age, how well you'll tolerate chemotherapy, how far your cancer has progressed, and whether you’re eligible for a stem cell transplant. Typically, chemotherapy regimens for multiple myeloma include 3 or 4 medications. Several alternative medications to Farydak (panobinostat) are available, including lenalidomide (Revlimid) and cyclophosphamide (Cytoxan), which are taken by mouth. These medications are often used in combination with other chemotherapy medications to destroy or attack cancer cells. Keep in mind that there are currently no medications that can cure multiple myeloma, but treatment can help slow cancer cell growth. Talk with your provider to determine which multiple myeloma treatment is best for you.